Working… Menu

YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00450398
Recruitment Status : Unknown
Verified January 2008 by Y's Therapeutics, Inc..
Recruitment status was:  Active, not recruiting
First Posted : March 22, 2007
Last Update Posted : January 29, 2008
Information provided by:
Y's Therapeutics, Inc.

Brief Summary:
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of ischemia reperfusion injury following liver transplantation by administering YSPSL into the liver graft directly ex vivo via the portal vein and to the recipient intravenously prior to reperfusion. Recently, P-selectin expression has been associated in liver grafts with prolonged cold storage times and rejection. By examining biomarkers of IRI including P-selectin by immunohistochemistry and/or quantitative PCR, liver histology and hepatic blood flow using established techniques, the goal of this study is to evaluate the feasibility of using these modalities for future studies of safety and efficacy.

Condition or disease Intervention/treatment Phase
Liver Diseases Drug: YSPSL Drug: Placebo Phase 2

Detailed Description:
This will be a single-center, single-dose study. The study will be a randomized, double-blind, placebo-controlled, single-dose study. Patients who are undergoing cadaveric orthotopic liver transplantation and are at risk for development of DGF, based upon known risk factors, will be eligible to participate in the study. 12 patients will be enrolled in the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation
Study Start Date : March 2007
Actual Primary Completion Date : December 2007
Estimated Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
Other Names:
  • rPSGL-Ig
  • recombinant P-selectin glycoprotein ligand-Ig

Placebo Comparator: 2 Drug: Placebo
Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
Other Name: Viaspan

Primary Outcome Measures :
  1. Delayed graft function post transplant [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Liver function parameters through 6 months post transplant [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient will be a recipient of a primary (first) ABO compatible cadaveric liver allograft;
  2. Patient's age is >=18 years;
  3. Patient is not a recipient of a multivisceral transplant or simultaneous kidney transplant;
  4. Patient has not undergone prior organ or cellular transplant of any type;
  5. Patient has a Model for End Stage Liver Disease (MELD) score of <28;
  6. Cold ischemia time (CIT) anticipated to be less than 12 hours;
  7. Donor liver procured by UCLA liver team;
  8. Veno-veno bypass is not planned to be used for the patient (e.g. no prior surgery or other factor that indicates a risk for excessive blood loss and therefore a need for veno-veno bypass +/- autologous recovery during surgery);
  9. For patients who are women of childbearing potential, patient has a negative pregnancy test (either urine or serum) within 48 hours prior to transplant;
  10. Patient (male and female) is willing to use an acceptable form of birth control for at least 3 months post-treatment; and
  11. Patient is willing and able to sign informed consent.

Exclusion Criteria:

  1. Patient has a prior organ transplant of any type;
  2. Patient has known allergic or intolerance reactions to human immune globulins, antibodies, or components of the formulation or known contraindication to administration of YSPSL;
  3. Patient has an uncontrolled active infection (on antibiotics with controlled infection is not an exclusion) ;
  4. Patient has active Hepatitis B virus (HBV)/transplant for HBV related cirrhosis;
  5. Patient has previously participated in this study or another study with YSPSL;
  6. Patient has received investigational therapy within 90 days prior to the transplant procedure;
  7. Patient has current drug or alcohol abuse or, in the opinion of the investigator, is at risk for poor compliance with the visits in this protocol (no drug testing required);
  8. Patient is a pregnant or nursing female, a female of childbearing potential planning to become pregnant within the duration of this study, or is not practicing birth control;
  9. Patient is planned to receive a living donor liver transplant;
  10. Patient lives >200 miles away or otherwise is not able to participate in study follow-up visits;
  11. Donor body mass index >28;
  12. Donor liver biopsy >20% macrosteototic fat;
  13. Donor age >65.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00450398

Layout table for location information
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Y's Therapeutics, Inc.
Layout table for investigator information
Study Director: Stefan Hemmerich, PhD Y's Therapeutics, Inc.

Layout table for additonal information
Responsible Party: Stefan Hemmerich, PhD, RAC, Y's Therapeutics Inc. Identifier: NCT00450398     History of Changes
Other Study ID Numbers: YSPSL-0002-PF
First Posted: March 22, 2007    Key Record Dates
Last Update Posted: January 29, 2008
Last Verified: January 2008
Keywords provided by Y's Therapeutics, Inc.:
Delayed graft function
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Delayed Graft Function
Digestive System Diseases
Pathologic Processes